Quick Answer
Jade Biosciences, Inc. reported Diluted EPS of $3.19 per share (loss) for fiscal year 2025.
Jade Biosciences, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.19 | -30.7% |
| 2024 | -$2.44 | +15.0% |
| 2023 | -$2.87 | -36.7% |
| 2022 | -$2.10 | -12.3% |
| 2021 | -$1.87 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.48 | +90.7% | +44.2% |
| June 30, 2025 | -$0.86 | -352.6% | -855.6% |
| March 31, 2025 | -$0.09 | +89.2% | +98.3% |
| September 30, 2024 | -$5.16 | -626.8% | -2615.8% |
| June 30, 2024 | -$0.19 | +75.0% | +77.1% |
| March 31, 2024 | -$0.83 | -23.9% | -16.9% |
| September 30, 2023 | -$0.71 | -26.8% | +6.6% |
| June 30, 2023 | -$0.76 | -55.1% | -13.4% |
- Jade Biosciences, Inc. showed a decrease of -30.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Jade Biosciences, Inc.’s diluted eps has declined by 70.6% (from $1.87 per share (loss) to $3.19 per share (loss)).
- The most recent figure is from Jade Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: